Literature DB >> 15302747

The management of status epilepticus.

Paul E Marik1, Joseph Varon.   

Abstract

Status epilepticus is a major medical emergency associated with significant morbidity and mortality. Status epilepticus is best defined as a continuous, generalized, convulsive seizure lasting > 5 min, or two or more seizures during which the patient does not return to baseline consciousness. Lorazepam in a dose of 0.1 mg/kg is the drug of first choice for terminating status epilepticus. Patients who continue to have clinical or EEG evidence of seizure activity after treatment with lorazepam should be considered to have refractory status epileptics and should be treated with a continuous infusion of propofol or midazolam. This article reviews current information regarding the management of status epilepticus in adults.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302747     DOI: 10.1378/chest.126.2.582

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

Review 1.  Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.

Authors:  Derek J Roberts; Babar Haroon; Richard I Hall
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

2.  Anticonvulsant therapy for status epilepticus.

Authors:  Kameshwar Prasad; Pudukode R Krishnan; Khaldoon Al-Roomi; Reginald Sequeira
Journal:  Br J Clin Pharmacol       Date:  2007-04-18       Impact factor: 4.335

3.  The use of lacosamide in refractory status epilepticus.

Authors:  Haley Goodwin; Holly E Hinson; Kenneth M Shermock; Navaz Karanjia; John J Lewin
Journal:  Neurocrit Care       Date:  2011-06       Impact factor: 3.210

4.  Prolonged refractory status epilepticus following acute traumatic brain injury: a case report of excellent neurological recovery.

Authors:  Adam D Peets; Luc R Berthiaume; Sean M Bagshaw; Paolo Federico; Christopher J Doig; David A Zygun
Journal:  Crit Care       Date:  2005-10-27       Impact factor: 9.097

5.  Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal.

Authors:  Riley J Lizotte; John A Kappes; Billie J Bartel; Katie M Hayes; Veronica L Lesselyoung
Journal:  Clin Pharmacol       Date:  2014-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.